Cisplatin-based chemotherapy may greatly enhance patient prognosis; however, chemotherapy resistance remains an obstacle to curing patients with non-small cell lung cancer (NSCLC). The aim of the present study was to explore the microRNAs (miRs) that could regulate cisplatin sensitivity and provide a potential treatment method for cisplatin resistance in clinical. Results from the present study revealed that miR-29a overexpression enhanced and miR-29a inhibition reduced the sensitivity of two NSCLC cell lines, A549 and H1650, to cisplatin treatment. In addition, reduced miR-29a expression levels were observed in cisplatin-resistant A549 cells (A549rCDDP), and increased expression of miR-29a augmented cisplatin-induced inhibition of proliferation and apoptosis in A549rCDDP cells. These data indicated that miR-29a expression may be involved in the development of cisplatin resistance. miR-29a was revealed to negatively regulate REV3-like DNA-directed polymerase ζ catalytic subunit (REV3L) expression in both A549 and H1650 cells; elevated expression of REV3L in A549rCDDP cells was also detected. REV3L encodes the catalytic subunit of DNA polymerase ζ and was hypothesized, based on results from the online tool TargetScan 7.1, to be a target gene of miR-29a; this was confirmed with a dual luciferase assay. Cells treated with a very low concentration of cisplatin exhibited a significant reduction in proliferation and cell cycle arrest at the G2/M phase in REV3L-knockdown as well as in miR-29a-upregulated A549 cells. Notably, reduced miR-29a expression and an increase in REV3L mRNA expression were observed in tumor tissues from patients with NSCLC. Additionally, a negative correlation between miR-29a and REV3L mRNA expression levels in tumor tissues from patients with NSCLC was observed; low expression of miR-29a and high expression of REV3L were closely associated with an advanced tumor-node-metastasis classification. The results of the present study suggested a pivotal role of miR-29a in mediating NSCLC cell sensitivity towards cisplatin through the regulation of REV3L.
Introduction
Lung cancer remains a leading cause of cancer-related mortality worldwide (1) . Non-small cell lung cancer (NSCLC) is a major type of lung cancer and is characterized by a poor prognosis with relatively low 5-year survival rate (2, 3) . Cisplatin-based chemotherapy is a standard procedure for the treatment of patients with NSCLC (4). Many patients initially respond to cisplatin-based chemotherapy, whereas certain patients with intrinsic resistance do not initially respond to cisplatin and others develop acquired resistance to cisplatin (5) . As a result, the 5-year survival rate for patients with NSCLC is only 17% (6) .
MicroRNAs (miRNAs) are non-coding, short single-chain nucleotide molecules (7) . Through binding to the 3'-untranslated region (UTR) of their target genes, miRNAs control a variety of physiological processes, including cell proliferation, cell migration and the cell cycle (8) . Dysregulation of miRNAs has been reported to contribute to the development of multiple diseases such as cancer (9, 10) . In addition, a number of miRNAs have been reported to be involved in the development of chemoresistance (11, 12) . miRNA (miR)-29 has been demonstrated to sensitize ovarian cancer cells to cisplatin treatment, and represents a potential therapeutic target (13) . However, whether and how miR-29 contributes to the development of cisplatin resistance in NSCLC remains unknown.
REV3-like DNA-directed polymerase ζ catalytic subunit (REV3L) encodes the catalytic subunit of DNA polymerase ζ, which is responsible for translesional replication (14) ; this
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function makes REV3L a cancer susceptibility candidate gene. A previous study reported that a c.460T>C variant in the REV3L 3'UTR affected the binding ability of miRNAs on REV3L mRNA and may contribute to lung cancer initiation (15) . Despite its role in cancer initiation, overexpression of REV3L has been reported to promote cell survival and the development of cisplatin resistance in human fibroblasts (16) .
In the present study, the expression of miR-29a was demonstrated to determine the sensitivity of A549 and H1650 cells to cisplatin. Furthermore, miR-29a expression was reduced in the cisplatin resistant A549 cell line (A549rCDDP), and increased miR-29a expression resensitized A549rCDDP cells to cisplatin. REV3L was confirmed to be a target gene of miR-29a. Further investigations revealed that the silencing of REV3L expression and the overexpression of miR-29a in A549 cells that were treated with a low concentration of cisplatin may significantly reduce cell proliferation, inhibition and cell cycle arrest at the G2/M phase. In addition, a decrease in miR-29a expression and an increase in REV3L expression were observed in cisplatin-resistant A549rCDDP cells. Gene expression analysis in tumor tissues from patients with NSCLC revealed a negative correlation between miR-29a and REV3L mRNA expression. In conclusion, results from the present study indicated that miR-29a may enhance NSCLC cell sensitivity to cisplatin treatment through the regulation of REV3L expression.
Materials and methods
Cell culture. The human NSCLC cell lines A549 and H1650, and 293 cells were purchased from American Type Culture Collection (Manassas, VA, USA), The A549 cisplatin-resistant sub-line, A549rCDDP, was obtained from The Cancer Hospital of Peking Union Medical College, Chinese Academy of Medical Sciences (Beijing, China). All cell lines were cultured in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum (HyClone; GE Healthcare Life Sciences, Logan, UT, USA) in a humid incubator with 5% CO 2 . For A549rCDDP cells, the complete culture medium was supplemented with 2 mg/l cisplatin (Selleck Chemicals, Houston, TX, USA). For cisplatin treatment conditions, the culture medium of A549, H1650 or A549rCDDP cells was supplemented with cisplatin (2.5, 5, 10 and 20 μg/ml; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) for the indicated times (24, 48 and 72 h).
Small interfering (si)RNA transfection. Two REV3L siRNAs (#1, 5'-GAU CAC AGG UUU GUG CCAG-3'; and #2, 5'-AGA CUG AGU GAG UCA CCUG-3') and a control siRNA were purchased from Invitrogen (Thermo Fisher Scientific, Inc.). Cells (2x10 5 ) were seeded in 6-well plates and cultured for 24 h; the siRNAs were individually mixed with Lipofectamine ® RNAiMAX (Invitrogen; Thermo Fisher Scientific, Inc.) and added into the cell culture medium at a final concentration of 0.01 µM and incubated for 72 h according to the manufacturer's instructions. At 72 h after transfection, cells were collected for the subsequent experiments.
miRNA transfection. Cells were transfected with 50 nmol/l miR-29a mimics (5'-UAG CAC CAU CUG AAA UCG GUUA-3') or miR-NC mimics (5'-UAA CCA CUU UCA CAU GGU CCUA-3'), miR-29a inhibitor (5'-UAA CCG AUU UCA GAU GGU GCUA-3') or miR-NC inhibitor (5'-UAA CCG AAU UCA CAU GGU CCUA-3') using Lipofectamine ® 2000 (Thermo Fisher Scientific, Inc.). In brief, cells (2x10 5 ) were seeded in a 6-well plate and incubated to 60-70% confluence. At 24 h after transfection, cells were collected for the subsequent experiments.
Cell cycle assay. For cell cycle analysis, cells were stained with propidium iodide (PI; Invitrogen; Thermo Fisher Scientific, Inc.). Briefly, following different treatments (control siRNA + miR-NC mimics + vehicle; control siRNA + miR-NC mimics + cisplatin; REV3L siRNA1 + miR-NC mimics + cisplatin; REV3L siRNA2 + miR-NC mimics + cisplatin; and control siRNA + miR-29a mimics + cisplatin) in five groups, cells were collected, washed with PBS and fixed in 70% ethanol at 4˚C overnight. Annexin V (5 μl) and PI (2.5 μl) were subsequently added to the cell suspension, and cell distribution was analyzed by flow cytometry. The cell number at each phase was analyzed using FloJo software (version 7.6.3; FlowJo LLC, Ashland, OR, USA).
RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
MiRNeasy Mini kit (Qiagen, Inc. Valencia, CA, USA) was used to extract total RNA from cells, according to the manufacturer's instructions. An M-MLV Reverse Transcriptase kit (Thermo Fisher Scientific, Inc.) was used to synthesize cDNA. qPCR was performed using SYBR Premix Ex Taq (Takara Bio, Inc., Otsu, Japan) on a CFX96 Real-Time PCR Detection System (Bio-Rad Laboratories, Hercules, CA, USA). GAPDH and U6 were used as internal controls for mRNA and miRNA, respectively. The primers were as follows: miR-29a, 5'-TAG CAC CAT CTG AAA TCG-3' (forward) and 5'-CAC ACC AGC ACT GACTA-3' (reverse); GAPDH, 5'-TGA ACT GAA AGC TCT CCACC-3' (forward) and 5'-CTG ATG TAC CAG TTG GGGAA-3' (reverse); U6, 5'-CTC GCT TCG GCA GCACA-3' (forward), 5'-AAC GCT TCA CGA ATT TGCGT-3' (reverse); REV3L, 5'-GCT CCA GTA TGT GTA CCA TCT TGT-3' (forward) and 5'-ATG GAT ATC TCG AAG TAA CAC GTC-3' (reverse). The 2 -ΔΔCq method was used to calculate relative gene expression (17) .
Western blotting. Cell lysates (100 µl; 2x10 6 cells) were prepared using radioimmunoprecipitation assay lysis buffer (Beyotime Institute of Biotechnology, Haimen, China) containing 2 µl protease inhibitor (Sigma-Aldrich; Merck KGaA). Briefly, the concentration of each protein sample was determined by bicinchoninic acid assay kit (Beyotime Institute of Biotechnology), and the total protein (20 μg/lane) extracted from each sample was separated by SDS-PAGE on 8% gels and transferred to polyvinylidene fluoride membranes (EMD Millipore, Billerica, MA, USA). The membranes were blocked in 5% non-fat milk and incubated with primary antibodies against REV3L (1:1,000; catalog no. GTX17515; GeneTex, Inc., Irvine, CA, USA) and GAPDH (1:10,000; catalog no. G8795; Sigma-Aldrich; Merck KGaA) at 4˚C overnight, followed by incubation with anti-rabbit peroxidase-conjugated secondary antibody (1:80,000; catalog no. a0545; Sigma-Aldrich; Merck KGaA) at room temperature for 1 h. Protein bands were visualized using Enhanced Chemiluminescence detection reagents (Thermo Fisher Scientific, Inc. USA). GAPDH served as a loading control.
Cell viability assay. Cell viability was determined by Cell
Counting Kit-8 (Dojindo Molecular Technologies, Inc., Kumamoto, Japan). For the detection of miR-29a on cisplatin induced cell viability, cells were seeded in a 96-well plate and subsequently exposed to vehicle (0.9% NaCl as control for ciaplatin) or cisplatin treatments (2.5, 5, 10 and 20 µg/ml) for 72 h.
For the determining the effect of miR-29a on cisplatin induced changes of cell proliferation, cells were treated with cisplatin (5 µg/ml) for 72 h. Subsequently, cells (2x10 5 ) were seeded in a 6-well plate and transfected with 50 nmol/l miR-29a mimics, miR-29a inhibitor or NC using Lipofectamine ® 2000 Table I . Association between miR-29a or REV3L and clinicopathological factors. (Thermo Fisher Scientific, Inc.). Subsequently, at 24 h after transfection, cells were collected for the subsequent experiments.
To determine the effect of REV3L on cell viability, REV3L siRNA (0.01 µM) or control siRNA (Thermo Fisher Scientific, Inc.) was transfected into cells which were treated with cisplatin (2 µg/ml) by Lipofectamine ® RNAiMAX (Invitrogen; Thermo Fisher Scientific, Inc.). At 72 h after transfection, cells were collected for the subsequent experiments. Briefly, 10 µl CCK-8 was added to the culture medium of each well and incubated for 2 h. The absorbance was measured at 450 nm with a microplate reader (Bio-Rad Laboratories, Inc.).
Subsequently, 10 µl CCK-8 was added to the culture medium of each well and incubated for 2 h. The absorbance was measured at 450 nm with a microplate reader (Bio-Rad Laboratories).
Cell apoptosis assay. Cells were collected by trypsinization and cell apoptosis was detected using an Annexin V-fluorescein isothiocyanate/PI cell apoptosis kit (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's instructions. Briefly, cells were suspended in Annexin binding buffer, and PI and Annexin V were added to the cell suspension. Cells were analyzed with a BD FACSCalibur flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA). Luciferase reporter assay. The wild-type (WT) REV3L 3'UTR sequence was amplified from cDNA of 293 cells and inserted into pGL-3 (Promega Corporation, Madison, WI, USA). REV3L 3'UTR-mutant (Mut) was constructed using PrimeSTAR Mutagenesis Basal kit (Takara Bio, Inc.). The 293 cells were co-transfected with pGL3-REV3L 3'UTR-WT or pGL3-REV3L 3'UTR-Mut and miR-29a mimics or miR-negative control (NC) mimics, and an internal control Renilla plasmid. Luciferase activity and Renilla activity were measured at 24 h post-transfection using a Dual Luciferase Reporter Assay kit (Promega Corporation), according to the manufacturer's instructions.
Patients. NSCLC tissues and adjacent normal liver tissues (located ≥2 cm from the tumor margins) were obtained from 30 patients (20 male and 10 female; 9 patients aged <60 years old and 21 patients aged ≥60 years old) who received surgery at Zhejiang Cancer Hospital (Zhejiang, China) and Shaoxing People's Hospital (Shaoxing, China; Table I ). Patients that received chemotherapy or radiotherapy were excluded from the study. Tissues were removed and stored at -80˚C. The present study was approved by the ethics committee of Zhejiang Cancer Hospital, and written informed consent was obtained from each patient prior to surgery and enrolment in the study.
Prediction of the target of miR-29a. TargetScan 7.1 was used to predict target sequences of miR-29a in the 3'UTR of REV3L (www.targetscan.org/vert_71/).
Statistical analysis. All statistical analyses were carried out using GraphPad Prism 5.0 software (GraphPad Software, Inc., La Jolla, CA, USA). Data are presented as the mean ± standard deviation. Statistically significant differences between two groups were analyzed using Student's t-test. Differences between multiple groups were analyzed with one-way ANOVA, followed by a Newman-Keuls post-hoc test. Correlations were made using Pearson's correlation coefficient. P<0.05 was considered to indicate a statistically significant difference.
Results

miR-29a expression is associated with cisplatin sensitivity in NSCLC cells.
To explore whether miR-29a expression affected the sensitivity of NSCLC cells to cisplatin, miR-29a mimics were used to increase miR-29a expression in A549 cells (Fig. 1A) . miR-29a overexpression reduced the viability and increased cisplatin sensitivity of cisplatin-sensitive A549 and H1650 cells, compared with the cells transfected with miR-NC mimics (Fig. 1B and  C, respectively) . Conversely, cells transfected an miR-29a inhibitor exhibited decreased miR-29a expression levels, increased viability and a reduction in sensitivity of A549 and H1650 cells to cisplatin exposure, compared with miR-NC-transfected cells (Fig. 1D-F) . These data suggested that miR-29a expression may be involved in cisplatin sensitivity of NSCLC cells.
Reduced miR-29a expression is associated with development of cisplatin resistance of A549 cells.
The contribution of miR-29a dysregulation to the development of cisplatin resistance in NSCLC cells was investigated. Compared with parental A549 cells, treatment of cisplatin only slightly reduced cell viability of cisplatin-resistant A549rCDDP cells ( Fig. 2A) , which indicated a relative insensitivity of these cells to cisplatin. RT-qPCR confirmed a significantly decreased expression level of miR-29a in A549rCDDP cells compared with A549 cells (Fig. 2B) . Transfection of miR-29a mimics enhanced the reduction in viability induced by cisplatin treatment in A549rCDDP cells, compared with miR-NC transfected cells (Fig. 2C) . It was also revealed that miR-29a overexpression significantly reduced cell proliferation in A549rCDDP cells treated with 5 µg/ml cisplatin, compared with miR-NC-transfected cell (Fig. 2D) . In addition, miR-29a overexpression significantly increased cisplatin-induced apoptosis (Fig. 2E) . These data suggested that reduced miR-29a expression may be involved in the development of cisplatin resistance in NSCLC cells.
miR-29a downregulates REV3L expression in NSCLC cells. REV3L is involved in the DNA repair pathway and is an indicator of chemotherapy sensitivity in several cancer types (18) . In A549 and H1650 cells, overexpression of miR-29a significantly decreased REV3L mRNA expression, compared with miR-NC-transfected cells (Fig. 3A) . Western blot analysis further demonstrated a notable reduction of REV3L protein expression in miR-29a-transfected cells (Fig. 3B ). In addition, higher REV3L mRNA and protein expression levels were detected in A549rCDDP cells, compared with A549 cells (Fig. 3C and D) . A549rCDDP cells transfected with miR-29a mimics exhibited a significant reduction in REV3L mRNA and protein expression levels, compared with miR-NC-transfected cells (Fig. 3E and F) . These results suggested a potential Figure 6 . miR-29a expression is negatively correlated with REV3L mRNA levels in NSCLC tumor tissues. (A) miR-29a expression levels were significantly lower in tumoral tissues from patients with NSCLC compared with adjacent normal tissues. (B) REV3L mRNA levels were significantly elevated in tumoral tissues from patients with NSCLC compared with adjacent normal tissues. (C) A negative correlation was identified between miR-29a and REV3L mRNA expression levels in NSCLC tumor tissues, as determined by Pearson correlation analysis. *** P<0.001. miR, microRNA; NSCLC, non-small cell lung cancer; REV3L, REV3-like DNA-directed polymerase ζ catalytic subunit.
role for miR29a and REV3L in the development of cisplatin resistance.
REV3L was a direct target of miR-29a. TargetScan 7.1 was used to predict target sequences of miR-29a in the 3'UTR of REV3L (Fig. 4A) . To confirm the direct regulatory relationship between miR-29a and REV3L, a dual luciferase assay was performed in 293 cells. Transfection of miR-29a mimics, but not miR-NC mimics, significantly reduced luciferase activity in cells transfected with REV3L 3'UTR-WT (Fig. 4B) ; no significant differences in luciferase activity were identified in cells co-transfected with REV3L 3'UTR-Mut. These data demonstrated that miR-29a may inhibit REV3L expression by binding to its 3'UTR.
miR-29a regulates cisplatin sensitivity of NSCLC cells through REV3L. REV3L is the catalytic subunit of DNA polymerase ζ, which is involved in translesional DNA synthesis (14) . Variations in REV3L have previously been demonstrated to lead to altered cell cycle distribution and, therefore, an altered sensitivity to chemotherapy (18) . REV3L siRNA1 and REV3L siRNA2 significantly decreased REV3L mRNA (Fig. 5A ) and protein level (Fig. 5B ) in A549 cells. Although treatment with a low concentration of cisplatin (2 µg/ml) alone (control siRNA + miR-NC mimics + cisplatin) did not affect the cell cycle compared with untreated control cells, a significant enrichment of cells in the G2/M phase was observed in REV3L-siRNA-transfected A549 cells treated with 2 µg/ml cisplatin ( Fig. 5C and D) . Similarly, miR-29a overexpression also induced G2/M arrest in A549 cells exposed to low-dose cisplatin ( Fig. 5C and D) . In addition, knockdown of REV3L expression or miR-29a overexpression significantly inhibited cell proliferation in the presence of cisplatin (2 µg/ml) compared with cells treated with cisplatin (2 µg/ml) only (Fig. 5E ). These results further validated the potential role of miR-29a in the regulation of cisplatin sensitivity of A549 cells; this regulation may be achieved through the downregulation of REV3L expression and increased cisplatin-induced G2/M arrest.
miR-29a expression is inversely correlated with REV3L mRNA expression in tumor tissues from patients with NSCLC.
To investigate the function of miR-29a and REV3L in patients with NSCLC, RT-qPCR was used to detect miR-29a and REV3L mRNA expression levels in tumoral and adjacent normal tissues (Fig. 6) . A significant decrease in miR-29a expression was observed in tumoral tissues compared with adjacent normal tissues (Fig. 6A) , whereas REV3L mRNA expression was elevated in tumoral tissues compared with normal tissues (Fig. 6B) . Notably, correlation analysis indicated that miR-29a expression was inversely correlated with REV3L mRNA expression in tumor tissues from patients with NSCLC (Fig. 6C) . Statistical analysis of the associations between miR-29a expression, REV3L mRNA expression and clinicopathological factors reveled that low expression of miR-29a and high expression of REV3L were closely associated with advanced TNM stage (Table I) . No significant associations were identified between miR-29a and REV3L expression with age, sex or metastatic status of the patients with NSCLC (Table I) .
Discussion
Resistance towards cisplatin-based chemotherapy is a major obstacle for the treatment of patients with NSCLC (19) . Although many proteins and miRNAs have been identified as drivers of chemoresistance (20) (21) (22) , further investigation is required to elucidate the complicated underlying mechanisms. In the present study, miR-29a was revealed to potentially regulate the sensitivity of NSCLC cells to cisplatin treatment. miR-29a was also predicted and confirmed to directly regulate REV3L expression, and therefore antagonize cisplatin resistance in A549rCDDP cells.
Recently, a number of reports have demonstrated that dysregulation of miRNA networks leads to the development of drug resistance in a number of cancers (23, 24) . In NSCLC, several miRNAs have been reported to contribute to the development of cisplatin resistance (25, 26) . miR-29a was demonstrated to act as a tumor suppressor in NSCLC by regulating oncogene expression, such as LIM and SH3 protein 1, in several in vitro studies (27, 28) . Consistent with these findings, the present study observed a decrease in miR-29a expression in NSCLC tumoral tissues. Downregulation of miR-29a has also been reported to be involved in the development of cisplatin resistance in ovarian cancer cells in vitro and in vivo (13) . The present study revealed that altered miR-29a expression affected the sensitivity of NSCLC cells to cisplatin treatment. In A549 and H1650 cells, downregulation of miR-29a partially reversed cisplatin-induced cell growth arrest, whereas upregulation of miR-29a sensitized cells to cisplatin treatment. Furthermore, there was a notable decrease in miR-29a expression in cisplatin-resistant A549rCDDP cells compared to their A549 cell counterpart. Therefore, it was suggested that miR-29a may promote the sensitivity of NSCLC cells to cisplatin, and loss of miR-29a may be responsible for cisplatin resistance in NSCLC.
REV3L is the catalytic subunit of DNA polymerase ζ, which is involved in translesional DNA synthesis (14) . The role of REV3L in cancer progression is controversial. For example, low expression of REV3L was observed in colon carcinomas compared with normal tissues, which suggested a role as a tumor suppressor (29) . By contrast, another study reported that REV3L depletion induced cell growth arrest in cancer cells of different origins, and identified REV3L as an oncogene (30) . As for chemotherapy resistance, upregulation of REV3L was previously demonstrated to serve a crucial role in many cancer types, including NSCLC, through regulation of DNA repair (16, 31, 32) . In the present study, an elevated expression level of REV3L was observed in A549rCDDP cells. In addition, REV3L was predicted and confirmed to be directly regulated by miR-29a. Silencing of REV3L or overexpression of miR-29a inhibited cell growth and increased accumulation of cells in the G2/M phase in cells co-treated with cisplatin. This was consistent with a previous study that demonstrated that depletion of REV3L led to cumulative DNA damage, and resulted in inhibition of cell proliferation and G2/M arrest (30) . Furthermore, results from the present study indicated that decreased miR-29a expression may contribute to the elevation of REV3L expression in A549rCDDP cells, and overexpression of miR-29a may reverse cisplatin resistance and induce growth arrest and apoptosis in A549rCDDP cells treated with cisplatin. Therefore, miR-29a/REV3L may promote the development of cisplatin resistance in NSCLC cells. The results of the present study provided further validation that REV3L depletion may amend cisplatin-based chemotherapy, and revealed that miR-29a may target REV3L to enhance cisplatin sensitivity of NSCLC cells.
In conclusion, the present study demonstrated that miR-29a positively regulates the sensitivity of NSCLC cells to cisplatin via direct suppression of REV3L expression. Downregulation of miR-29a led to cisplatin resistance in NSCLC cells and may be a promising prognostic tool and a target for the treatment of patients with NSCLC.
